Retrospective

**HCV Next in Retrospect:**
Looking Back at ‘Your Guide to the Age After Interferon’

**Nov. 25, 2013**

**Olysio approved as hepatitis C treatment**

The FDA has approved Olysio (simeprevir, Janssen) as part of an antiviral treatment regimen with pegylated interferon and ribavirin for the treatment of patients with chronic hepatitis C genotype 1.

**Dec. 6, 2013**

**FDA approves once-daily oral Sovaldi as hepatitis C treatment**

The FDA today approved once-daily oral nucleotide analog Sovaldi (sofosbuvir, Gilead Sciences) as part of an antiviral regimen for the treatment of hepatitis C patients with genotypes 1, 2, 3 or 4, according to a news release.

**Oct. 10, 2014**

**FDA approves Harvoni for HCV treatment**

Using the breakthrough therapy designation, the FDA approved the first combination pill for treatment of chronic hepatitis C virus genotype 1 that does not require interferon or ribavirin for administration, according to an agency release.
Combination therapy aimed at multiple viral and host targets could lead to effective and short duration therapy. ... If such regimens were safe, well tolerated and affordable, that would be an important step in achieving global HCV eradication.

William Sievert, MD

"Making hepatitis C a disease of the past comes with a price, but it will save lives and money in the long term.

John Ward, MD

FDA approves Viekira Pak for treatment of HCV

The FDA today approved a treatment for patients with hepatitis C virus genotype 1 infection, including those with cirrhosis, according to a press release.

FDA approves Daklinza for chronic hepatitis C genotype 3 infections

FDA approves Daklinza for chronic hepatitis C genotype 3 infections
FDA approves Sovaldi, Harvoni for pediatric patients with HCV

The FDA has approved Sovaldi and Harvoni as supplemental applications for the treatment of hepatitis C in children aged 12 to 17 years, according to an FDA news release.

FDA approves Epclusa for all HCV genotypes

The FDA announced it has approved Epclusa for the treatment of all chronic hepatitis C virus genotypes in adults with and without cirrhosis. For patients with moderate to severe cirrhosis, it is approved in combination with ribavirin.

FDA approves Vosevi for HCV

FDA announced the approval of Vosevi for the treatment of adults with chronic hepatitis C genotypes 1 through 6, according to an agency press release.

“...The failure rate of these drugs is 3%. ... The risk of dying on the waiting list is greater than that. It is certainly not an ethical issue in terms of risk-benefit.”

Robert S. Brown Jr., MD, MPH
FDA approves Mavyret, the first pan-genotypic 8-week treatment for HCV

The FDA approved AbbVie’s Mavyret to treat adults with hepatitis C genotypes 1 through 6 without cirrhosis or with mild cirrhosis, including those who failed previous direct-acting antiviral treatment, according to an agency press release. The new approval indicates only 8 weeks of treatment needed in treatment-naive patients without cirrhosis.